Retinal Degeneration Fund makes mission-related investments in therapeutic companies with projects nearing clinical testing.
Retinal Degeneration Fund helps in accelerating life-changing outcomes for people with retinal degenerations through direct mission-related investments in therapeutic companies.The Retinal Degeneration Fund (RD Fund) is a not-for-profit subsidiary of the Foundation Fighting Blindness launched in 2018.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 14, 2022
SparingVision
|
Series B | €75M | Biotechnology | — |
Jun 15, 2022
Nacuity Pharmaceuticals
|
Series B | $16.50M | Health Care | — |
Jan 5, 2022
SalioGen Therapeutics
|
Series B | $115M | Biotechnology | — |
Sep 22, 2021
Opus Genetics
|
Seed | $19M | Health Care | Yes |
May 18, 2021
Vedere Bio ll
|
Series A | $77M | Biotechnology | — |
Retinal Degeneration Fund has had 1 exits. Retinal Degeneration Fund most notable exits include Vedere Bio ll
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Oct 29, 2020 | Vedere Bio ll | M&A | Biotechnology | Detail |